GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » EPS (Diluted)

Kiadis Pharma NV (XAMS:KDS) EPS (Diluted) : €-2.24 (TTM As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV EPS (Diluted)?

Kiadis Pharma NV's Earnings per Share (Diluted) for the six months ended in Dec. 2020 was €-1.67. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was €-2.24.

Kiadis Pharma NV's EPS (Basic) for the six months ended in Dec. 2020 was €-1.67. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2020 was €-2.24.

Kiadis Pharma NV's EPS without NRI for the six months ended in Dec. 2020 was €-1.67. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2020 was €-2.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Kiadis Pharma NV EPS (Diluted) Historical Data

The historical data trend for Kiadis Pharma NV's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV EPS (Diluted) Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only -1.08 -1.14 -1.46 -1.92 -2.24

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.72 -1.03 -0.89 -0.57 -1.67

Competitive Comparison of Kiadis Pharma NV's EPS (Diluted)

For the Biotechnology subindustry, Kiadis Pharma NV's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's PE Ratio distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's PE Ratio falls into.



Kiadis Pharma NV EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Kiadis Pharma NV's Diluted EPS for the fiscal year that ended in Dec. 2020 is calculated as

Diluted EPS (A: Dec. 2020 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-81.94-0)/36.615
=-2.24

Kiadis Pharma NV's Diluted EPS for the quarter that ended in Dec. 2020 is calculated as

Diluted EPS (Q: Dec. 2020 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-63.096-0)/40.135
=-1.57

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiadis Pharma NV  (XAMS:KDS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Kiadis Pharma NV EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (XAMS:KDS) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines